source
- Why early de-risking is redefining the path to INDLonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.Fierce Biotech · 15d ago↗ source
- STAT+: Celcuity’s breast cancer drug approved, its firstFDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The ReadoutSTAT · 15d ago↗ source
- Understanding Agentic AI in Clinical DevelopmentEarlier this year, my colleague Matt Harrington suggested that clinical leaders should stop asking whether their organizations have an “AI strategy”, not because strategy doesn’t matter, but becaus…Fierce Biotech · 15d ago↗ source